EIP Pharma

EIP Pharma is a U.S.-based developer of new drugs, primarily focusing on Alzheimer's disease treatments. Its drug candidate neflamapimod (also known as VX-745) achieved positive results in a Phase 2a clinical trial for patients with early-stage Alzheimer's Disease (AD).